NLS Pharmaceutics AG (NLSP) - Margin bathi reged

NLSP (NLS Pharmaceutics) - tandha merek perusahaan

Relative gross margin demonstrates the potential of Quilience, which targets narcolepsy via an innovative dopamine mechanism, while 0.00 serves as the current parameter value. Current financial health is based on capital reserves, as the clinical testing stage precludes operational cash flow. The authority of NLS Pharmaceutics AG (NLSP) in treating rare cognitive disorders helps patients return to their normal rhythm of life.

NLSP - Rentabilitas reged NLS Pharmaceutics Ltd. ing rentang 04.07.2022 - 31.10.2025

Rincian metrik komprehensif lan analitis NLS Pharma (NLSP)

- rega pasar lan target rega analis:
Analisis dhasar perusahaan:NLS Pharmaceutics AG NLSP
Produk seri NLS Pharmaceutics Ltd.

Gross margin measures the efficiency of direct production by determining the profit share after deducting the cost of goods sold. Gross margin dynamics allow an investor to promptly assess the profitability of operational processes and the risk of an overvalued asset. This ratio is calculated as the difference between revenue and production costs divided by total sales, which is critically important for evaluating the R&D potential of NLS Pharmaceutics AG (NLSP) in developing medications for the treatment of ADHD.